Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.104 USD | +16.20% | +13.66% | -38.68% |
Mar. 27 | Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab | CI |
Feb. 15 | Kintara Therapeutics Continues to Evaluate Strategic Options | CI |
- Stock
- Equities
- Stock Kintara Therapeutics, Inc. - Nasdaq
- News Kintara Therapeutics, Inc.